Trial of Robotic Versus Laparoscopic-assisted Radical Resection for Rectal Cancer (TRVL)
A Randomized, Prospective Trial of Robotic Versus Laparoscopic-assisted Radical Resection for Rectal Cancer in Urinary, Erectile Function and Anal Function
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Phase
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Patients who are acceptable to two surgical procedures for the robot- assisted or laparoscopy-assisted rectal cancer, are willing to randomized trial;
- 2. Matching the diagnostic criteria;
- 3. Aged 18-70 years old;
- 4. Preoperative TNM staging (CT, laparoscopic exploration): cT1-3N0-3M0 (excluding M1, T4);
- 5. Preoperative ASA 3 scores;
- 6. There was no history of malignancy, no other malignant tumors by preoperative examination;
- 7. Without undergoing definitive treatment, such as radiotherapy, chemotherapy or immunotherapy preoperatively;
- 8. The informed consent form was signed by the patient himself(herself)or his principal agent;
- 9. In accordance with the international erectile function questionnaire (IIEF) urinary function scale, The urinary sexual function are normal.
Exclusion Criteria:
- 1. Age less than 18 years old or more than 70 years old;
- 2. Previous psychiatric patients or patients refused to sign the informed consent;
- 3. Attending other related clinical studies on surgical treatment of rectal cancer;
- 4. The patient has a history of malignant tumor, or a combination of other malignant tumors;
- 5. Patients have been treated with definitive treatment: radiotherapy, chemotherapy or immunotherapy;
- 6. Patients had received otherper abdominal operations (except for laparoscopic cholecystectomy);
- 7. ASA >3;
- 8. Laparoscopic surgical contraindications: such as severe heart lung disease; abdominal wall hernia; diaphragmatic hernia; coagulation disorder; portal hypertension; pregnancy, etc.;
- 9. Those who has been confirmed to be unable to do a radical resection (T4 stage) for local advanced tumor;
- 10. Those who have urination sexual dysfunction preoperatively.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Robot-assisted total mesorectal excision
Robot-assisted total mesorectal excision (RTME) for rectal cancer.
Two different RTME procedures were chose to personalized patients.
Generally, when the tumor located within 5-15cm from the anal verge, low anterior resection (LAR) was employed, and tumor located below 5cm, abdominoperineal resection (APR) was applied usually.
|
The Da Vinci Surgical System may help to protect subtle anatomical structure and provide more functional protection when compared to laparoscopic surgery.
This study aimed to compare RTME and laparoscopic total mesorectal excision (LTME) for rectal cancer with regard to Urinary, sexual function and sphincter- preservation outcomes.
|
|
Active Comparator: Laparoscopic total mesorectal excision
Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer was performed.
The Urinary, sexual function and sphincter- preservation outcomes were evaluated.
|
Traditional laparoscopic total mesorectal excision (LTME) for rectal cancer.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of sexual and urinary dysfunction
Time Frame: One years after surgery
|
One years after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
disease-free survival(DFS )
Time Frame: 3 years disease-free survival
|
DFS was defined as from the date of randomization to the date of tumor recurrence or death from any cause
|
3 years disease-free survival
|
|
Anus preservation rate
Time Frame: One years after surgery
|
One years after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2015(43)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.